CASI Pharmaceuticals (CASI) Receivables - Net (2021 - 2025)
Historic Receivables - Net for Pharmaceuticals (CASI) over the last 5 years, with Q2 2025 value amounting to $5.4 million.
- Pharmaceuticals' Receivables - Net fell 9992.09% to $5.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.4 million, marking a year-over-year decrease of 9992.09%. This contributed to the annual value of $15.3 million for FY2024, which is 9983.93% down from last year.
- Latest data reveals that Pharmaceuticals reported Receivables - Net of $5.4 million as of Q2 2025, which was down 9992.09% from $7.6 billion recorded in Q1 2025.
- Over the past 5 years, Pharmaceuticals' Receivables - Net peaked at $12.5 billion during Q2 2023, and registered a low of $5.4 million during Q2 2025.
- Moreover, its 5-year median value for Receivables - Net was $15.3 million (2024), whereas its average is $4.1 billion.
- Within the past 5 years, the most significant YoY rise in Pharmaceuticals' Receivables - Net was 12965926.24% (2025), while the steepest drop was 9992.09% (2025).
- Quarter analysis of 5 years shows Pharmaceuticals' Receivables - Net stood at $9.8 million in 2021, then skyrocketed by 32.34% to $13.0 million in 2022, then skyrocketed by 73522.14% to $9.6 billion in 2023, then tumbled by 99.84% to $15.3 million in 2024, then tumbled by 65.05% to $5.4 million in 2025.
- Its last three reported values are $5.4 million in Q2 2025, $7.6 billion for Q1 2025, and $15.3 million during Q4 2024.